Abstract
Quipazine, first identified in the 1960s, has been the topic of >1000 published papers. On the basis of available 5-HT2 serotonin receptor radioligand binding data and various preclinical studies, it might be thought that quipazine bears the hallmarks of a classical hallucinogen or psychedelic agent – agents currently being examined for their potential use in treating certain neuropsychiatric disorders. Nevertheless, by definition, such agents require the availability of human data, which, in the case of quipazine, are lacking. Because quipazine is also a 5-HT3 receptor agonist, future human studies with this agent might prove problematic because 5-HT3 agonists are known to produce emesis. Nevertheless, continued investigation of novel quipazine analogs with modified pharmacological profiles might prove worthwhile.
Reference72 articles.
1. FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray. 16 February 2022. US Food and Drug Administration, Silver Spring, MD, USA. Available at [accessed 30 November 2022].
2. Glennon RA, Iversen LE. Antidepressants. In: Glennon RA, volume editor. Burger’s Medicinal Chemistry. Wiley; 2021. pp. 331–386.
3. The neural basis of psychedelic action.;Nat Neurosci,2022
4. On the pharmacology of 2-(1-piperazinyl)quinoline.;J Pharmacol Exp Ther,1966
5. Similarities between the pharmacological actions of quipazine and serotonin.;Eur J Pharmacol,1969
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献